ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02254109
Recruitment Status : Completed
First Posted : October 1, 2014
Last Update Posted : October 1, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to evaluate safety, tolerability, and pharmacokinetics of BEA 2180 BR in Japanese healthy volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: BEA 2180 BR - rising dose Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers
Study Start Date : April 2008
Actual Primary Completion Date : October 2008

Arm Intervention/treatment
Experimental: BEA 2180 BR - rising dose Drug: BEA 2180 BR - rising dose
Placebo Comparator: Placebo Drug: Placebo



Primary Outcome Measures :
  1. Number of subjects with abnormal findings in physical examination [ Time Frame: up to 28 days after last dose administration ]
  2. Number of subjects with clinically significant changes in vital signs [ Time Frame: up to 28 days after last dose administration ]
    Blood pressure and pulse rate

  3. Number of subjects with clinically significant changes in 12-lead electrocardiogram (ECG) [ Time Frame: up to 28 days after last dose administration ]
  4. Number of subjects with abnormal changes in laboratory parameters [ Time Frame: up to 28 days after last dose administration ]
  5. Number of subjects with adverse events [ Time Frame: up to 28 days after last dose administration ]
  6. Assessment of tolerability by the investigator on a 4-point scale [ Time Frame: 28 days after last dose administration ]

Secondary Outcome Measures :
  1. Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: up to 648:00 hours ]
  2. tmax (time from dosing to maximum measured concentration of the analyte in plasma) [ Time Frame: up to 648:00 hours ]
  3. AUCτ (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ) [ Time Frame: up to 648:00 hours ]
  4. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable concentration at tz) [ Time Frame: up to 648:00 hours ]
  5. Aeτ (amount of analyte that is eliminated in urine over a uniform dosing interval τ) [ Time Frame: up to 648:00 hours ]
  6. feτ (fraction of analyte eliminated in urine over a uniform dosing interval τ) [ Time Frame: up to 648:00 hours ]
  7. CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2) [ Time Frame: up to 648:00 hours ]
  8. Cmin,ss (minimum concentration of the analyte in plasma at steady state) [ Time Frame: up to 648:00 hours ]
  9. Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose) [ Time Frame: up to 648:00 hours ]
  10. λz,ss (terminal rate constant in plasma at steady state) [ Time Frame: up to 648:00 hours ]
  11. t1/2,ss (terminal half-life of the analyte in plasma at steady state) [ Time Frame: up to 648:00 hours ]
  12. MRTih,ss (mean residence time of the analyte in the body at steady state after inhalation administration) [ Time Frame: up to 648:00 hours ]
  13. CL/F,ss (apparent clearance of the analyte in the plasma at steady state following extravascular multiple dose administration) [ Time Frame: up to 648:00 hours ]
  14. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration) [ Time Frame: up to 648:00 hours ]
  15. Accumulation ratio of the analyte in plasma based on Cmax (RA,Cmax) [ Time Frame: up to 648:00 hours ]
  16. Accumulation ratio of the analyte in plasma based on AUC (RA,AUC) [ Time Frame: up to 648:00 hours ]
  17. Accumulation ratio of the analyte in plasma based on Ae (RA,Ae) [ Time Frame: up to 648:00 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy Japanese men:

    According to the results of a complete medical history, the physical examination, vital signs (blood pressure and pulse rate), 12-lead ECG, clinical laboratory tests

  2. Age ≥20 and ≤35 years
  3. Body mass index (BMI) ≥18.5 and ≤25 kg/m2
  4. Subjects must be able to inhale medication in a competent manner from the Respimat®
  5. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP)

Exclusion Criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Surgery of the gastrointestinal tract (except appendectomy)
  5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  6. History of relevant orthostatic hypotension, fainting spells or blackouts
  7. Chronic or relevant acute infections
  8. History of relevant allergy/hypersensitivity including allergy to drug or its excipients
  9. Intake of drugs with a long half-life (>24 hours) within one month or less than 10 half-lives of the respective drug before drug administration or during the trial
  10. Use of prescription or non-prescription drugs within 10 days before drug Administration or during the trial. However, over-the-counter (OTC) drugs for external application (such as lubricant eye drops for contact lens, insect bite reliever) shall be allowed
  11. Participation in another trial with an investigational drug within four months before drug administration or during the trial
  12. Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)
  13. Inability to refrain from smoking during the trial
  14. Alcohol abuse (≥60 g/day: corresponds to ca. 3 large bottles of beer, 3 gous (ca. 540 cc) of Japanese sake, 6 shots of whisky, 6 glasses of wine or 6 glasses of Japanese shochu, distilled alcoholic beverage)
  15. Drug abuse
  16. Blood donation (≥100 mL within four weeks before drug administration or during the trial)
  17. Excessive physical activities (within one week before drug administration or during the trial)
  18. Any laboratory value outside the reference range that is of clinical relevance
  19. Inability to comply with dietary regimen of trial site

    Exclusion criteria specific for this study:

  20. Occupational (professional) exposure to antimuscarinic substances (e.g., physician, nurse, pharmacist etc.; volunteers working for medical institutions, research institutions or herb gardens)
  21. History of glaucoma, urination difficulty (due to prostatic hyperplasia etc.)

Additional Information:
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02254109     History of Changes
Other Study ID Numbers: 1205.18
First Posted: October 1, 2014    Key Record Dates
Last Update Posted: October 1, 2014
Last Verified: September 2014